Dr. Aman Chauhan Presents Phase 1 Study on Neuroendocrine Tumors at ESMO 2025
Earlier from Tron
- ESMO Abstract “1709MO - Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)”
- Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025
- Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors
- Nanopharmaceutics Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma